document type sequence filename description exhibit text html head title title head body style font time roman time serif style margin nbsp style font time roman time serif margin text align right exhibit style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center license agreement style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent this license agreement ldquo agreement rdquo effective march ldquo effective date rdquo made between oxis biotech delaware corporation having place business north beverly drive beverly hill ldquo oxis rdquo multicell immunotherapeutics delaware corporation having place business cumberland street suite woonsocket hereinafter ldquo mcit rdquo style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent whereas mcit owns technology patent right field antibody drug conjugate style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent whereas oxis desire obtain license under mcit rsquo right field antibody drug conjugate term condition forth below style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent whereas mcit oxis have entered into research agreement ldquo rdquo effective march which this license agreement exhibit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent therefore consideration foregoing premise mutual covenant herein contained party hereby agree follows style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp definition style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent purpose this agreement term defined this section shall have respective meaning forth below style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo affiliate rdquo shall mean with respect person other person which directly indirectly control controlled under common control with such person person shall regarded control another person owns directly indirectly control least fifty percent voting stock other ownership interest other person directly indirectly posse power direct cause direction management policy other person mean whatsoever style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo competent authority rdquo shall mean collectively governmental entity each country supranational organization that responsible regulation licensed human therapeutic product intended exclusive field establishment maintenance protection right related licensed right including emea mhlw other applicable regulatory administrative agency country supranational organization that comparable counterpart foregoing style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo deliverable rdquo shall mean redacted antibody drug conjugate delivered mcit pursuant style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo emea rdquo shall mean european medicine agency which responsible evaluation human medicinal product european union successor thereto style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo exclusive field rdquo shall mean licensed human therapeutic product vivo treatment triple negative breast cancer multiple myeloma secondary osteoporosis human style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo rdquo shall mean food drug administration united state successor thereto style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo mcit right rdquo shall mean collectively mcit patent right mcit technology know right style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo mcit technology know right rdquo shall mean mcit trade secret other know right data information composition other technology including limited formula procedure protocol technique result experimentation testing arising from developed result under defined therein which necessary useful oxis make have made have used develop sell have sold seek regulatory approval market licensed human therapeutic product practice method process time claimed disclosed issued patent pending patent application within licensed patent right which otherwise relates technology style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align center confidential treatment requested style font time roman time serif margin text align center nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo mcit patent right rdquo shall mean mcit rsquo patent application listed appendix hereto including issue reissue renewal extension continuation continuation part division foreign counterpart style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo licensed human therapeutic product rdquo shall mean licensed product that synthesized intended vivo therapeutic human style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo licensed product rdquo shall mean antibody drug conjugate therapeutic product containing redacted that made used sold offered sale imported oxis affiliate absent license granted hereunder would infringe valid claim licensed patent right otherwise incorporate licensed technology know right convenience chemical structure alternative name redacted shown appendix attached hereto style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo licensed research product rdquo shall mean licensed product that synthesized intended research only preclinical study enabling study vitro vivo mammal other than human style font time roman time serif margin text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo rdquo shall mean drug application biological license application ldquo rdquo similar application marketing approval licensed human therapeutic product submitted foreign equivalent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo sale rdquo shall mean with respect licensed human therapeutic product gross sale price such licensed human therapeutic product invoiced oxis affiliate customer affiliate affiliate user such licensed human therapeutic product extent actually paid accrued oxis affiliate applicable credit allowance discount rebate chargebacks from account such customer nonconforming damaged dated returned licensed human therapeutic product freight insurance cost incurred oxis affiliate applicable transporting such licensed human therapeutic product such customer cash quantity trade discount rebate other price reduction such licensed human therapeutic product given such customer under price reduction program provided that such discount shall exceed gross sale price annual basis sale value added other direct incurred sale such licensed human therapeutic product such customer custom duty tariff surcharge other governmental charge incurred exporting importing such licensed human therapeutic product such customer style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo sublicensing revenue rdquo shall mean with respect licensed human therapeutic product aggregate cash consideration received oxis affiliate consideration sublicense under licensed patent right licensed know right oxis affiliate third party licensee with respect such licensed human therapeutic product including royalty received oxis affiliate based sale such licensed human therapeutic product such licensee excluding amount received reimburse oxis rsquo affiliate rsquo cost perform research development similar service conducted such licensed human therapeutic product after signing agreement with third party reimbursement patent other pocket expense relating such licensed human therapeutic product consideration purchase debt security oxis affiliate style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo person rdquo shall mean individual corporation partnership limited liability company trust business trust association joint stock company joint venture pool syndicate sole proprietorship unincorporated organization governmental authority other form entity specifically listed herein style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align center confidential treatment requested style font time roman time serif margin text align center nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo phase clinical trial rdquo shall mean human clinical trial that intended initially evaluate safety pharmacological effect licensed human therapeutic product subject that would otherwise satisfy requirement foreign equivalent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo phase clinical trial rdquo shall mean human clinical trial country that intended initially evaluate effectiveness licensed human therapeutic product particular indication indication patient with disease indication under study would otherwise satisfy requirement foreign equivalent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo phase clinical trial rdquo shall mean human clinical trial country result which could used establish safety efficacy licensed human therapeutic product basis would otherwise satisfy requirement foreign equivalent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo registration rdquo shall mean permit license authorization registration regulatory approval including required granted competent authority prerequisite development manufacturing packaging marketing selling product style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo research field rdquo shall mean licensed research product conduct clinical enabling study vitro vivo mammal other than human target treat triple negative breast cancer multiple myeloma secondary osteoporosis style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo royalty term rdquo shall mean with respect each licensed human therapeutic product each country longer term which valid claim remains effect would infringed license granted this agreement offer sale sale import such licensed human therapeutic product such country term during which licensed human therapeutic product made with using incorporating licensed technology know right offered sale sold imported such country style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo successful completion rdquo mean with respect specified human clinical trial achievement determined sponsor such trial primary clinical endpoint identified protocol such trial style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo territory rdquo shall mean worldwide style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo third party rdquo shall mean person other than mcit oxis their respective affiliate style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp ldquo valid claim rdquo shall mean claim issued unexpired patent included within licensed patent right which been held permanently revoked unenforceable invalid decision court other governmental agency competent jurisdiction unappealable unappealed within time allowed appeal which been admitted invalid unenforceable through reissue disclaimer otherwise style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp representation warranty style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp each party hereby represents warrant other party follows style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp such party corporation duly organized validly existing good standing under state which incorporated style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp such party corporate power authority legal right enter into this agreement perform obligation hereunder taken necessary corporate action part authorize execution delivery this agreement performance obligation hereunder this agreement been duly executed delivered behalf such party constitutes legal valid binding obligation enforceable against such party accordance with term style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp necessary consent approval authorization governmental authority other person required obtained such party connection with this agreement have been obtained style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp execution delivery this agreement performance such party rsquo obligation hereunder conflict with violate requirement applicable regulation conflict with constitute default under contractual obligation style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit representation warranty mcit hereby represents warrant covenant affiliate rsquo behalf that style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp knowledge inventor identified licensed patent right represent inventor licensor patent right accordance with united state patent inventor have assigned their full right title interest mcit patent right mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit sole owner mcit patent right mcit technology know right style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp execution delivery this agreement performance mcit will result breach violation constitute default under agreement instrument judgment order which mcit bound style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp there invention disclosure patent application issued patent other than mcit patent right which mcit ownership interest which discloses claim invention which reasonably necessary manufacture sale licensed human therapeutic product style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp knowledge sale offer sale importation licensed human therapeutic product practice mcit patent right mcit technology know infringe misappropriate third party patent other intellectual property right being acknowledged agreed oxis that neither mcit oxis engaged outside patent counsel conduct freedom operate search with respect mcit patent right mcit technology know style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit received claim writing from third party contesting validity enforceability licensability ownership mcit patent right mcit technology know style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp there pending declaratory judgment action interference opposition reissue proceeding examination involving mcit patent right mcit technology know style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis representation warranty oxis hereby represents warrant covenant affiliate rsquo behalf that style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp neither oxis affiliate shall mcit patent right mcit technology know other than expressly forth herein neither oxis affiliate shall misappropriate mcit patent right mcit technology know time style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis affiliate shall comply with intellectual property confidentiality provision forth herein style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis affiliate shall attempt reverse engineer mcit technology know licensed product manufactured behalf mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp execution delivery this agreement performance oxis will result breach violation constitute default under agreement instrument judgment order which oxis bound style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp except forth section mcit make guarantee warranty either express implied oxis specifically excludes without limitation warranty merchantability fitness particular purpose with respect mcit patent right mcit technology know information data furnished hereunder under nothing this agreement shall construed style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp warranty representation that anything made used sold otherwise disposed under license under this agreement will free from infringement valid issued patent third party style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp requirement that mcit shall file patent application secure patent maintain defend patent patent application force style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp granting implication estoppel otherwise license right under patent mcit regardless whether such other patent dominant subordinate other patent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp obligation bring prosecute action suit against third party infringement style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp conferring right advertising publicity otherwise trademark tradename mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit make representation warranty kind either express implied assumes responsibility whatsoever with respect manufacture sale offer sale import transfer other disposition licensed product style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nothing herein will construed warranty representation scope validity claim mcit patent right that mcit patent right enforceable style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp license grant style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp subject term this agreement mcit hereby grant oxis style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent bearing terminable indivisible transferable right license with right grant sublicenses consume deliverable solely necessary conduct study within research field style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent bearing royalty bearing terminable indivisible transferable exclusive right license with right grant sublicenses sell licensed human therapeutic product territory within exclusive field mcit shall assert mcit patent right against oxis permitted sublicensee long such party exercise right preceding sentence permitted nothing contained this agreement shall grant oxis interest mcit patent right mcit technology know until exercise option under section payment amount thereunder license mcit patent right mcit technology know style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis rsquo right grant sublicenses license section above affiliate third party contingent upon sublicensee agreeing abide term provision this agreement oxis remains fully liable performance sublicensee rsquo obligation hereunder oxis notifying mcit grant sublicense providing mcit upon mcit request copy sublicense agreement style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp subject term this agreement effective only upon exercise option under section payment amount thereunder mcit shall additionally grant oxis bearing royalty bearing terminable indivisible transferable worldwide right license without right sublicense mcit patent right mcit technology know solely extent required make have made licensed human therapeutic product sale only exclusive field territory style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp period year following date this agreement mcit shall provide such technical assistance oxis oxis reasonably request regarding licensed product oxis shall mcit documented reasonable pocket cost providing such technical assistance style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit acknowledges agrees that oxis shall registration licensed human therapeutic product sale exclusive field each country territory additionally mcit acknowledges agrees that oxis shall have right conduct clinical clinical development activity licensed human therapeutic product territory using licensed research product incident such research activity vitro vivo mammal other than human permitted section above avoidance doubt oxis shall have right licensed research product treat human vivo mcit hereby grant oxis right reference have full access other registration other regulatory document that relate licensed human therapeutic product including inds blas ndas dmfs whether independent document part chemistry manufacturing control information supplement amendment update foregoing purpose this section ldquo right reference rdquo oxis shall have right license right reference licensee affiliate provided said licensee affiliate comply fully with applicable term herein mcit shall promptly notify oxis written oral notice received from inspection competent authority relating such registration shall promptly inform oxis response such written notice inspection resolution issue raised such competent authority oxis shall entitled attend meeting participate telephone call with competent authority including without limitation meeting preparation meeting ordination preparation minute style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp notwithstanding anything contrary herein right specifically expressly granted license above oxis shall reserved remain always with mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp financial consideration style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp technology license style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp consideration inter alia license section herein oxis shall mcit refundable technology license five hundred thousand dollar which shall payable according following payment schedule style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent hundred fifty thousand dollar shall paid mcit immediately upon effective date this agreement style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent hundred twenty five thousand dollar shall paid mcit thirty calendar after effective date this agreement style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent hundred twenty five thousand dollar shall paid mcit sixty calendar after effective date this agreement style font time roman time serif margin text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp royalty style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp subject royalty term term condition this agreement oxis shall mcit royalty with respect each licensed human therapeutic product equal three percent sale such licensed human therapeutic product oxis affiliate thirty percent licensing revenue such licensed human therapeutic product style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp licensed human therapeutic product component covered valid claim covered licensed technology know right then oxis shall mcit royalty with respect each such licensed human therapeutic product equal half percent sale such licensed human therapeutic product oxis affiliate twenty five percent licensing revenue such licensed human therapeutic product style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp third party royalty oxis affiliate licensee required royalty third party order exercise right hereunder sell offer sale import licensed human therapeutic product then oxis shall have right credit percent such third party royalty payment against royalty owing mcit under section above with respect sale such licensed human therapeutic product such country provided however that oxis shall reduce amount royalty paid mcit under section above reason this section with respect sale such licensed human therapeutic product such country than half percent sale such licensed human therapeutic product such country style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall mcit following milestone payment within thirty following first achievement applicable milestone style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp five hundred thousand dollar upon dosing first patient phase clinical trial each licensed human therapeutic product anywhere territory style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp seven hundred fifty thousand dollar upon dosing first patient phase clinical trial each licensed human therapeutic product anywhere territory style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp million thousand dollar upon dosing first patient phase clinical trial each licensed human therapeutic product anywhere territory style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp million dollar upon filing equivalent each licensed human therapeutic product anywhere territory style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp million dollar upon first marketing approval competent regulatory authority each licensed human therapeutic product anywhere territory style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp manufacturing right licensed human therapeutic product style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit hereby grant oxis option obtain worldwide license make have made licensed human therapeutic product sale exclusive field ldquo option rdquo style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp option shall expire three year from effective date ldquo option period rdquo must exercised full prior lapse foregoing option period style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis exercise option during term this agreement delivering mcit prior lapse option period written notice election exercise option million dollar failure deliver both preceding sentence during term this agreement prior lapse option period shall void option style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp report payment style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp before last business january april july october each calendar year this agreement oxis shall submit mcit written report with respect preceding calendar quarter ldquo payment report rdquo stating style font time roman time serif margin text align justify nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent sale made oxis affiliate during such quarter style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent case transfer licensed human therapeutic product affiliate oxis sale rental lease such licensed human therapeutic product affiliate third party sale oxis affiliate sale affiliate third party during such quarter style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent sale sublicensees during such quarter style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent amount accruing received oxis from sublicensees during such quarter style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent calculation under section amount licensor making reference applicable subsection thereof style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp within thirty submission each payment report oxis shall make payment mcit amount calendar quarter covered payment report amount shall paid united state dollar payment shall made oxis bank wire transfer mcit rsquo bank payment report shall mailed following address style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent multicell immunotherapeutics style font time roman time serif margin text align justify text indent cumberland street suite style font time roman time serif margin text align justify text indent woonsocket style font time roman time serif margin text align justify text indent attn chief executive officer style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp payment style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp royalty shown have accrued each royalty report provided under section above shall date such royalty report payment royalty whole part made advance such date style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp time legal restriction prevent prompt remittance part royalty with respect country territory where licensed human therapeutic product sold oxis shall have right sole discretion make such payment depositing amount thereof local currency mcit rsquo account bank other depository institution such country royalty rate specified this agreement should exceed permissible rate established country royalty rate sale such country shall adjusted highest legally permissible government approved rate style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall entitled deduct amount withholding value added other levy charge with respect such amount other than united state payable oxis affiliate licensee required withheld oxis affiliate licensee extent oxis affiliate licensee appropriate governmental authority behalf licensor such levy charge oxis shall reasonable effort minimize such levy charge required withheld behalf licensor oxis affiliate licensee oxis promptly shall deliver licensor proof payment such levy other charge together with copy communication from with such governmental authority with respect thereto style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp research development obligation style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall conduct such research development preclinical human clinical trial oxis determines necessary desirable obtain regulatory approval manufacture market such licensed human therapeutic product oxis determines commercially feasible territory otherwise required commence phase clinical trial licensed human therapeutic product before anniversary effective date shall commercially reasonable effort obtain regulatory approval market following approval commence marketing market each such licensed human therapeutic product such country territory oxis determines commercially feasible style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall maintain record sufficient detail good scientific manner which shall reflect work done result achieved performance research development regarding licensed human therapeutic product style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp often than every month anniversary after effective date oxis shall report writing mcit progress made toward objective forth above style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent notwithstanding anything else contrary oxis shall required commence phase clinical trial licensed human therapeutic product anywhere territory before anniversary effective date style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp patent style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis determines that desire patent application made covering licensed human therapeutic product oxis will appoint qualified counsel after reasonable consultation with mcit whom mcit reasonable objection consultation with patent counsel appointed mcit oxis will prepare prosecute such application mcit rsquo name country designated oxis oxis will handle filing patent application with appropriate patent office oxis shall promptly provide copy mcit proposed patent application filing oxis shall good faith take into consideration advice suggestion mcit patent counsel with regard each such proposed patent application communication oxis will reimburse mcit reasonable expense incurred will reasonable expense incurred future filing prosecuting such application including attorney annuity issue working maintenance renewal charge each party hereto agrees cooperate with other party execute lawful paper instrument make rightful oath declaration provide consultation assistance necessary preparation prosecution maintenance reinforcement such patent application patent such patent application letter patent issued thereupon shall added mcit patent right subject license herein style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp each party shall notify other party substantial infringement territory known such party mcit patent right shall provide other party with available evidence such infringement style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit shall have right exclusively determine appropriate course action enforce mcit patent right otherwise abate infringement thereof take refrain from taking appropriate action enforce mcit patent right defend declaratory judgment seeking invalidate hold mcit patent right unenforceable control litigation other enforcement action enter into permit settlement such litigation declaratory judgment other enforcement action with respect mcit patent right each case mcit rsquo name mcit within hundred twenty receipt notice from oxis abate infringement file suit enforce mcit patent right against least infringing party territory oxis shall have right take whatever action deems appropriate enforce mcit patent right provided however that within thirty after receipt notice oxis rsquo intent file such suit mcit shall have right jointly prosecute such suit fund half frac cost such suit party controlling such enforcement action shall settle action otherwise consent adverse judgment such action that diminishes right interest controlling party without prior written consent other party monies recovered upon final judgment settlement such suit enforce licensed patent right shall shared after reimbursement each party rsquo legal expense basis each party style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp suit enforce defend mcit patent right pursuant this section party control such suit shall request expense controlling party reasonably cooperate extent possible have employee testify when requested make available relevant record paper information sample specimen like style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp confidentiality style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp during term this agreement period five year following expiration earlier termination hereof each party shall maintain confidence information other party that disclosed other party identified acknowledged confidential time disclosure ldquo confidential information rdquo shall disclose grant confidential information except with respect oxis expressly permitted below with respect mcit except need know basis those director officer affiliate employee permitted licensee permitted assignee agent consultant clinical investigator contractor extent such disclosure reasonably necessary connection mcit rsquo performing obligation exercising right under this agreement extent that disclosure authorized this agreement prior disclosure each party hereto shall obtain agreement such person hold confidence make confidential information purpose other than those permitted this agreement each party shall notify other promptly upon discovery unauthorized disclosure other party rsquo confidential information style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp notwithstanding anything else contrary herein disclosure oxis confidential information employee officer director oxis prohibited unless said individual need know information order oxis perform obligation exercise right under this agreement said individual bound written obligation confidentiality intellectual property ownership oxis restrictive corresponding obligation binding oxis hereunder under style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp notwithstanding anything else contrary herein disclosure oxis confidential information third party including limited consultant agent independent contractor investor business partner prohibited except that oxis permitted disclose portion confidential information employee redacted have need know information order oxis able exercise right licensed oxis under section only provided minimum information disclosed required such purpose each such recipient each case bound oxis written obligation confidentiality intellectual property ownership restrictive corresponding obligation binding oxis hereunder under style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp confidentiality obligation contained section above shall apply extent that receiving party ldquo recipient rdquo required disclose information regulation order governmental agency court competent jurisdiction disclose information governmental agency purpose obtaining approval test market product provided either case that recipient shall provide written notice thereof other party sufficient opportunity object such disclosure request confidential treatment thereof recipient demonstrate that nbsp disclosed information public knowledge time such disclosure recipient thereafter became public knowledge other than result action recipient violation hereof nbsp disclosed information rightfully known recipient shown written record prior date disclosure recipient other party hereunder nbsp disclosed information disclosed recipient unrestricted basis from source unrelated party this agreement under duty confidentiality other party disclosed information independently developed recipient without confidential information disclosed other party breach this agreement style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin margin bottom text align center confidential treatment requested style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp disclosure term this agreement style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp except otherwise provided section mcit oxis shall disclose term condition this agreement third party without prior consent other party hereto provided however that each party hereto indicate existence this license with other party term condition filing with security exchange commission ldquo rdquo style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp each party issue press release stating that they have entered into this agreement said party rsquo press release must approved other party advance publication such approval will unreasonably withheld style font time roman time serif margin text align justify nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp prohibition against other party rsquo name style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp neither party will other party rsquo name insignia symbol combination thereof name employee purpose whatsoever without other party rsquo prior written consent provided however that each party hereto indicate existence this license with other party filing style font time roman time serif margin text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp compliance with governmental obligation style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp notwithstanding provision this agreement mcit disclaims obligation liability arising under license provision this agreement oxis charged governmental action complying with fails comply with governmental regulation course taking step bring licensed human therapeutic product point practical application style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall comply with governmental request directed oxis upon reasonable notice from mcit licensor provide information assistance reasonably necessary comply with legitimate governmental request style font time roman time serif margin text align justify nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall insure that research development marketing under this agreement complies with government regulation force effect including limited federal state municipal legislation style font time roman time serif margin text align justify nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp indemnification style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall defend indemnify hold mcit director officer employee agent affiliate harmless from loss liability damage expense including attorney rsquo cost incurred result claim demand action proceeding arising breach representation warranty covenant oxis section mcit patent right mcit technology know oxis whether authorized manufacture storage transportation sale licensed human therapeutic product licensed research product vivo human negligence willful misconduct oxis performance obligation under this agreement style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp mcit promptly shall notify oxis liability action respect which mcit intends claim such indemnification oxis shall have right assume defense thereof with counsel selected oxis indemnity agreement this section nbsp shall apply amount paid settlement loss claim damage liability action such settlement effected without consent oxis which consent shall withheld unreasonably failure deliver notice oxis within reasonable time after commencement such action prejudicial ability defend such action shall relieve oxis liability licensor under this section nbsp omission deliver notice oxis will relieve liability that have licensor otherwise than under this section nbsp mcit under this section nbsp employee agent shall cooperate fully with oxis legal representative investigation defense action claim liability covered this indemnification style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis shall maintain product liability insurance with respect research development manufacture sale licensed human therapeutic product oxis such amount oxis customarily maintains with respect research development manufacture sale similar product oxis shall maintain such insurance long continues research develop manufacture sell licensed human therapeutic product thereafter long oxis customarily maintains insurance covering research development manufacture sale similar product style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp notwithstanding anything contrary herein except oxis rsquo violation mcit rsquo intellectual property right exceeding scope license right herein party shall liable indirect special incidental consequential exemplary damage whether foreseeable that related this agreement breach thereof transaction resulting from this agreement loss goodwill profit lost business however characterized from other cause whatsoever even though party have been advised otherwise know possibility such damage style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp force majeure style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp neither party shall held liable responsible other party deemed have defaulted under breached this agreement failure delay fulfilling performing term this agreement extent long such failure delay caused result from cause beyond reasonable control affected party including limited fire flood embargo whether declared terrorism insurrection riot civil commotion strike lockout other labor disturbance omission delay acting governmental authority other party style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp export control style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp this agreement made subject restriction concerning export product technical information from united state america which imposed from time time government united state america furthermore each party hereto agrees that will export export directly indirectly technical information acquired from other under this agreement product using such technical information country which united state government agency thereof time export requires export license other governmental approval without first obtaining written consent from department commerce other agency united state government when required applicable statute regulation style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp termination style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp subject section below this agreement shall expire expiration oxis rsquo obligation royalty mcit under section above license granted under section option fully exercised permitted herein shall effective time prior such expiration style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis terminate this agreement sole discretion upon thirty prior written notice mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp except otherwise provided section nbsp mcit terminate this agreement upon after breach provision this agreement oxis oxis cured such breach within thirty after receipt express written notice thereof mcit style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp expiration termination this agreement shall relieve party obligation accruing prior such expiration termination provision section nbsp other provision which their term survive termination order give effect their term shall survive expiration termination this agreement style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp miscellaneous style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp consent notice report required permitted given made under this agreement party hereto other party shall writing delivered lawful mean such other party rsquo chief executive officer address indicated below such other address party shall have last furnished writing other party except otherwise provided this agreement shall effective upon receipt receiving party style font time roman time serif margin text align justify nbsp table cellpadding cellspacing style font time roman time serif margin margin bottom style vertical align text align justify style width style width text align left style text align justify multicell immunotherapeutics table style font time roman time serif margin cumberland street suite style font time roman time serif margin woonsocket style font time roman time serif margin text align justify nbsp table cellpadding cellspacing style font time roman time serif margin margin bottom style vertical align text align justify style width style width text align left style text align justify oxis biotech table style font time roman time serif margin text align justify north beverly drive style font time roman time serif margin text align justify beverly hill style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp payment made mcit required permitted under this agreement shall made follows bank wire transfer style font time roman time serif margin text indent nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width layout grid mode line text align right padding right account name style width layout grid mode line multicell immunotherapeutics style vertical align style layout grid mode line text align right padding right account number style layout grid mode line redacted style vertical align style layout grid mode line text align right padding right bank name style layout grid mode line redacted style vertical align style layout grid mode line text align right padding right bank address style font time roman time serif margin redacted style font time roman time serif margin redacted style font time roman time serif margin redacted style vertical align style layout grid mode line text align right padding right bank wire transfer routing number style layout grid mode line redacted table style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp neither party shall assign right obligation under this agreement without prior written consent other party provided however that either party without such consent assign this agreement right obligation hereunder affiliate nbsp connection with transfer sale substantially business which this agreement relates event merger consolidation change control similar transaction permitted assignee shall assume obligation assignor under this agreement style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp this agreement shall governed construed accordance with state california without regard conflict principle thereof style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp dispute controversy claim initiated either party arising resulting from relating this agreement performance either party obligation under this agreement other than nbsp dispute controversy claim regarding validity enforceability claim construction infringement patent right defense foregoing nbsp bona fide third party action proceeding filed instituted action proceeding third party against party this agreement whether before after termination this agreement shall finally resolved binding arbitration whenever party shall decide institute arbitration proceeding shall give written notice that effect other party such arbitration shall conducted under commercial arbitration rule american arbitration association panel three arbitrator appointed accordance with such rule such arbitration shall held francisco california method manner discovery such arbitration proceeding shall governed california code civil procedure sect including without limitation california code civil procedure sect style font time roman time serif margin text align center text indent nbsp style font time roman time serif margin text align center confidential treatment requested style font time roman time serif margin text align justify text indent nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align justify text indent arbitrator shall have authority grant specific performance allocate between party cost arbitration such equitable manner they determine judgment upon award rendered entered court having jurisdiction application made such court judicial acceptance award order enforcement case event shall demand arbitration made after date when institution legal equitable proceeding based upon such claim dispute other matter question would barred applicable statute limitation notwithstanding foregoing either party shall have right without waiving right remedy available such party under this agreement otherwise seek obtain from court competent jurisdiction interim provisional relief that necessary desirable protect right property such party pending selection arbitrator hereunder pending arbitrator rsquo determination dispute controversy claim hereunder style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp oxis will inform mcit within five business regulatory approval licensed human therapeutic product will assist mcit apply applicable extension exclusivity whether patent extension special protection certificate data exclusivity like style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp change modification extension termination waiver this agreement provision herein contained shall valid unless made writing signed duly authorized representative party hereto style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp this agreement embodies entire agreement between party supersedes prior representation understanding agreement between party regarding subject matter hereof there representation understanding agreement oral written between party regarding subject matter hereof that fully expressed herein style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp provision this agreement which determined invalid unenforceable jurisdiction shall ineffective extent such invalidity unenforceability such jurisdiction without rendering invalid unenforceable remaining provision hereof without affecting validity enforceability term this agreement other jurisdiction style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp waiver either party hereto right hereunder failure perform breach other party shall deemed waiver other right hereunder other breach failure said other party whether similar nature otherwise style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp this agreement executed more counterpart each which shall deemed original which together shall constitute same instrument style font time roman time serif margin text align justify text indent nbsp style font time roman time serif margin text align justify text indent witness thereof mcit oxis have caused this agreement executed their duly authorized representative year first written above style font time roman time serif margin text align justify nbsp table cellspacing cellpadding style font time roman time serif width border collapse collapse style vertical align style width layout grid mode line text align justify multicell immunotherapeutics style width layout grid mode line text align justify nbsp style width layout grid mode line text align justify oxis biotech style vertical align style layout grid mode line text align justify nbsp style layout grid mode line text align justify nbsp style layout grid mode line text align justify nbsp style vertical align style border bottom black solid layout grid mode line text align justify gerald newmin style layout grid mode line text align justify nbsp style border bottom black solid layout grid mode line text align justify anthony cataldo style vertical align style layout grid mode line text align justify gerald newmin style layout grid mode line text align justify nbsp style layout grid mode line text align justify anthony cataldo style vertical align style layout grid mode line text align justify nbsp style layout grid mode line text align justify nbsp style layout grid mode line text align justify nbsp style vertical align style border bottom black solid layout grid mode line text align justify chairman chief executive officer style layout grid mode line text align justify nbsp style border bottom black solid layout grid mode line text align justify chairman chief executive officer style vertical align style layout grid mode line text align justify title style layout grid mode line text align justify nbsp style layout grid mode line text align justify title table style font time roman time serif margin text align justify nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin style font time roman time serif margin text align center appendix style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center patent patent application style font time roman time serif margin text align center nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp redacted style font time roman time serif margin nbsp style font time roman time serif margin nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp redacted style font time roman time serif margin nbsp style font time roman time serif margin margin bottom text align center confidential treatment requested style font time roman time serif margin text align center nbsp field page sequence style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table style page break before always margin margin bottom table cellpadding cellspacing style width style text align center width nbsp table field page style font time roman time serif margin nbsp style font time roman time serif margin text align center appendix style font time roman time serif margin text align center nbsp style font time roman time serif margin text align center chemical composition matter style font time roman time serif margin text align center nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp redacted style margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp redacted style font time roman time serif margin text indent nbsp style font time roman time serif margin text indent nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp nbsp redacted style font time roman time serif margin text indent nbsp style font time roman time serif margin margin bottom text align center confidential treatment requested style font time roman time serif margin text align center nbsp field page sequence option last style margin margin bottom border bottom black solid table cellpadding cellspacing style width font size style text align center width field sequence type arabic name pageno field sequence table field page style font time roman time serif margin body html text document